NASDAQ · HTFLHealthcareSurgical Instruments

Heartflow financials

$49.83−0.18%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

QuarterQ2 '26
Jun 30
Q1 '26
Mar 31
Q4 '25
Dec 31
Q3 '25
Sep 30
Revenue$64.1M$52.6M$49.1M$46.3M
Gross profit$53.2M$42.2M$39.1M$35.4M
Gross margin83.0%80.2%79.5%76.5%
Operating income-$17.9M-$29.5M-$17.8M-$15.1M
Net income-$15.7M-$27.4M-$24.4M-$50.9M
Net margin−24.6%−52.1%−49.7%−109.9%
Diluted EPS$-0.18$-0.32$-0.28$-1.04
EBITDA-$16.7M-$20.6M-$16.4M-$13.8M
Operating cash flow-$8.6M-$30.1M-$10.6M-$3.0M
Free cash flow-$10.5M-$32.0M-$12.5M-$4.2M
Diluted shares86.4M85.6M85.8M49.1M

Balance sheet

Period endJun 30Mar 31Dec 31Sep 30
Cash & equivalents$34.4M$19.7M$44.8M$291.2M
Short-term investments$128.2M$138.6M$132.0M$0.00
Total debt$0.00$0.00$0.00$0.00
Total assets$344.5M$344.0M$359.5M$364.4M
Total liabilities$64.7M$58.3M$58.8M$109.8M
Shareholders' equity$279.7M$285.7M$300.6M$254.6M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology